For decades, Medicare paid for a kidney transplant and then, three years later, stopped paying for the drugs that keep the new organ alive. The 36-month cliff was one of the cruelest quirks in the program: a patient could receive a costly, life-saving transplant on Medicare’s dime, only to lose coverage for the immunosuppressive medications that prevent rejection, sometimes forcing a choice between the drugs and the rent. A benefit that took effect in 2023 closed that gap, extending anti-rejection drug coverage for life for the patients most at risk of falling through it.
The 36-month cliff and what changed in 2023
Under the old rule, Medicare coverage tied to a kidney transplant generally ended 36 months after the surgery for beneficiaries who had qualified through kidney failure rather than age or disability. Once that window closed, the transplant recipient was on the hook for immunosuppressive drugs that can run into the hundreds or thousands of dollars a month — indefinitely, because a transplanted kidney requires those medications for as long as it functions.
The consequences were measurable and grim. Patients who could not afford the drugs skipped doses, lost the transplanted organ to rejection, and returned to dialysis or the transplant waiting list, both far costlier than the pills that would have prevented the failure. The fix, created by Congress and administered by Medicare, established a new limited benefit that continues immunosuppressive drug coverage past the 36-month mark. Medicare’s rules for organ transplant services now reflect that ongoing coverage.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
How the Part B-ID benefit works, and its limits
The new coverage carries a formal name — the Medicare Part B immunosuppressive drug benefit, or Part B-ID — and it is deliberately narrow. It covers immunosuppressive drugs, and only those drugs. It does not restore full Medicare coverage for doctor visits, hospital stays, or any other care; a beneficiary relying on Part B-ID keeps drug coverage but not the rest of the program’s benefits.
The benefit is also a backstop, not a first option. It is available to a kidney transplant recipient whose regular Medicare has ended and who does not have other coverage that would pay for the drugs — no Medicaid, no employer plan, no other insurance with an immunosuppressive benefit. Someone who gains group coverage later is expected to use it instead. As the National Kidney Foundation has stressed, the program exists to catch the patients who would otherwise have nothing, not to layer on top of coverage they already hold.
That narrowness is the trade-off. The benefit solves the specific problem that was killing transplanted kidneys — unaffordable anti-rejection drugs — without pretending to be comprehensive health coverage. For a patient with no other insurance, that focused lifeline is precisely what keeps a transplant viable.
Signing up runs through the Social Security Administration rather than happening on its own. A transplant recipient whose regular Medicare is ending can enroll in Part B-ID by contacting Social Security, and the benefit was created by a 2020 law — the Consolidated Appropriations Act — that gave Medicare roughly two years to build the program before it opened on January 1, 2023. Because enrollment is an active step tied to the moment regular coverage lapses, the recipients most exposed are those who assume their transplant coverage simply rolls forward and never make the call.
What it costs and why the drugs are worth protecting
Part B-ID is not free. In 2026 it carries its own monthly premium of $121.60, higher for beneficiaries who owe an income-related adjustment, along with the standard Part B annual deductible of $283. After the deductible, the patient pays 20 percent of the Medicare-approved amount for the immunosuppressive drugs, the same coinsurance structure that applies to other Part B-covered medications.
Even with that cost-sharing, the benefit dramatically undercuts the alternative. A 20 percent share of a controlled drug regimen is a fraction of the full retail price a patient would face with no coverage at all, and it is a rounding error next to the cost of losing the organ. Dialysis alone runs to roughly six figures a year, and a second transplant, if one becomes available, is costlier still — to say nothing of the toll on the patient.
For low-income beneficiaries, the premium and coinsurance need not come entirely out of pocket. Someone who qualifies for a Medicare Savings Program, administered through the state Medicaid office, can have the Part B-ID premium paid on their behalf, and the same categories of assistance that help with other Medicare costs can apply to this benefit. Confirming eligibility for that help at the same time as enrolling is what keeps the program’s own price tag from becoming a fresh barrier for exactly the patients it was built to protect. It is also worth noting that these drugs are billed under Part B, not the Part D pharmacy benefit, so a recipient relying on Part B-ID does not need a separate drug plan to have the immunosuppressants covered.
The premium does mean the benefit requires active enrollment and ongoing payment; it is not automatic, and a transplant recipient who assumes coverage simply continues could find a gap. Confirming eligibility and signing up before regular Medicare lapses is the step that turns the law on paper into drugs in the medicine cabinet.
The larger point is that the 2023 change fixed a policy that had been penny-wise and pound-foolish for a generation — paying for the transplant, then abandoning the inexpensive drugs that protect the investment. For kidney-transplant patients without other coverage, the lifetime immunosuppressive benefit is the difference between keeping a functioning organ and watching a successful transplant fail for lack of a monthly prescription.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
